Takara Bio Inc. (JP:4974) has released an update.
Takara Bio Inc. reported that despite lower-than-expected net sales for the first six months of fiscal 2024, its operating and ordinary profits significantly surpassed forecasts due to reduced SG&A expenses and lower deferred income taxes. This led to a notable increase in net income attributable to owners of the parent compared to initial projections.
For further insights into JP:4974 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Paramount Global (NASDAQ:PARA) Adds an Ad-Supported Tier in Europe
- How Ford (NYSE:F) Looks to Solve Its Hydrogen Engine Problem
- The Intel (NASDAQ:INTC) “Coffee Debacle” Is Now Solved
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
